GSK Signals CBD Interest With Agreement For Potential Australian Launch
Executive Summary
GSK will evaluate the launch potential in Australia of a non-prescription CBD product currently being studied as a short-term treatment for sleep disturbances. The firm also has first refusal to negotiate the rights to market the product – developed by Cann Group – in other countries around the world.
You may also be interested in...
People On The Move: Appointments At Alliance Pharma, Stada And Cann
A round-up of the latest appointments in the consumer health market: Alliance Pharma appoints COO; Stada confirms Döbler as permanent CFO; and Cann Group hires CEO from Ipsen.
UK’s Chanelle McCoy Health Joins Race For World’s First OTC CBD Medicine
Ever since Australia's Therapeutic Goods Administration removed the prescription requirement for CBD, the race has been on to launch the world's first OTC CBD medicine. The UK's Chanelle McCoy Health has joined Haleon and local players McCann and Little Green Pharma in testing CBD for sleep with an eye on a 2023 product launch.
Why Spin Out? IQVIA Consumer Health On The Standalone Trend In OTC
Greater flexibility, a higher tolerance to risk, longer investment time-lines and access to a wider pool of next generation talent are some of the benefits to consumer health businesses when separating from their pharma parents, according to IQVIA Consumer Health.